Few studies have assessed the role of 24-h ambulatory blood pressure monitoring (ABPM) in adults with nondialysis chronic kidney disease (CKD). We examined the potential determinants of left ventricular hypertrophy (LVH) and mass index (LVMI) in this population.
We carried out a cross-sectional study on 69 stage 3b-5 CKD adults who had ABPM and transthoracic echocardiography performed simultaneously. Hypertension (HT) was defined as 24 h blood pressure (BP) of at least 130/80 mmHg. ABPM parameters considered were BP dipping status, BP load, and the BP night-time/daytime ratio. We performed stepwise backward multivariate linear and logistic regression to assess the determinants of LVH and LVMI. ABPM parameters were considered the main independent variables, whereas HT, angiotensin-converting enzyme inhibitor/angiotensin II receptor antagonist use, glomerular filtration rate of less than 30 ml/min/1.72 m2, diabetes, smoking, age, sex, hemoglobin, and parathyroid hormone levels were considered covariates.
LVH was present in 22 (31.8%) patients. In linear regression analysis, systolic [β=−13.8, 95% confidence interval (CI)=−26.3 to −1.3, P=0.031] and mean (β=−13.5, 95% CI=−25.7 to −1.2, P=0.031) nondipping status was associated with increased LVMI. BP load and night-time/daytime ABPM ratio were not associated with LVMI. In logistic regression analysis, systolic nondipping status (odds ratio=0.27, 95% CI=0.08–0.91, P=0.036) was associated with LVH. Among covariates, estimated glomerular filtration rate of less than 30 ml/min/1.72 m2 and HT were associated with LVH and increased LVMI. At 1-year follow-up, mean nondipping status on the initial ABPM remained associated significantly with increased LVMI (β=−19.8, 95% CI=−36.6 to −3.0, P=0.022).
These data confirm the high incidence of LVH among nonrenal replacement therapy CKD patients and suggest that the nondipping phenomenon on ABPM is associated independently with LVH and increased LVMI in this population.
Divisions of aGeneral Internal Medicine
cNephrology, Geneva University Hospitals, Geneva, Switzerland
*Belen Ponte and Patrick Saudan contributed equally to the writing of this article.
Correspondence to David A. Jaques, MD, Division of General Internal Medicine, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland Tel: +41 795 534 090; fax: +41 223 729 769; e-mail: email@example.com
Received March 23, 2018
Received in revised form May 15, 2018
Accepted May 25, 2018